Novartis: Sandoz' anti-rheumatic biosimilars match Remicade
(CercleFinance.com) - Sandoz, a Novartis division, said two long-term, Phase III studies showed that its anti-rheumatic biosimilars Zessly and Erelzi matched their reference biologic, J&J's Remicade, in terms of safety, efficacy and quality.
Novartis also said on Friday that real-world data has concluded that its drug Jakavi was associated with a reduction in the risk of death and dangerous blood clots for patients with polycythemia vera, a rare blood cancer.
Finally, Novartis highlighted on Friday a survey uncovering real-world impact of immune thrombocytopenia, a rare blood disease, on patients' life quality.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Novartis also said on Friday that real-world data has concluded that its drug Jakavi was associated with a reduction in the risk of death and dangerous blood clots for patients with polycythemia vera, a rare blood cancer.
Finally, Novartis highlighted on Friday a survey uncovering real-world impact of immune thrombocytopenia, a rare blood disease, on patients' life quality.
Copyright (c) 2018 CercleFinance.com. All rights reserved.